GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

London: GSK plc and Syndivia, a private biotechnology company focused on next-generation ADCs, have announced an agreement ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

--GSK has lately posted lower vaccine sales in China and the U.S., and faces pressure to show that its pipeline includes new blockbuster drugs to counter concerns about that slowdown, AJ Bell ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

Under the deal, France-based Syndivia will receive an upfront payment, as well as development and commercial milestone ...

GSK PLC closed 2.64% short of its 52-week high of £16.85, which the company reached on October 2nd.

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has announced the purchase of 555,000 of its own ordinary shares as part ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).